• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by ProKidney Corp.

    3/20/25 5:06:43 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PROK alert in real time by email
    S-8 1 s-8_2025_-_evergreen_inc.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 20, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    ProKidney Corp.

    (Exact name of registrant as specified in its charter)

    Cayman Islands

    98-1586514

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification Number)

    2000 Frontis Plaza Blvd., Ste 250

    Winston-Salem, NC 27103

    (Address, including zip code, of Principal Executive Offices)

    ProKidney Corp. 2022 Incentive Equity Plan

    (Full Title of the Plan)

    Bruce Culleton, M.D.

    Chief Executive Officer

    ProKidney Corp.

    2000 Frontis Plaza Blvd., Ste 250

    Winston-Salem, NC 27103

    Telephone: (336) 999-7028

    (Name, address and telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    

    Accelerated filer

    

    Non-accelerated filer

    

    Smaller reporting company

    

    Emerging growth company

    

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 


    EXPLANATORY NOTE

    This Registration Statement registers 14,587,406 additional Class A ordinary shares, par value $0.0001 per share (“Class A Ordinary Shares”), of ProKidney Corp. (the “Registrant”) under the Registrant’s 2022 Incentive Equity Plan (the “2022 Plan”), representing an increase of 14,587,406 Class A Ordinary Shares reserved for issuance under the 2022 Plan, effective January 1, 2025 by operation of the “evergreen” provision contained in the 2022 Plan. This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 of the Registrant relating to one or more employee benefit plans is effective (File Nos. 333-267414 and 333-270920). The information contained in the Registrant’s registration statements on Form S-8 (File Nos. 333-267414 and 333-270920), to the extent not otherwise amended or superseded by the contents hereof, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

    The following documents filed by the Registrant with the Commission are incorporated herein by reference:

    (a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 17, 2025;

    (b) The Registrant’s Current Report on Form 8-K, as filed with the Commission on January 21, 2025; and

    (c) The description of the Registrant’s securities contained in the Registrant’s registration statement on Form 8-A (File No. 001-40560), filed by the Registrant with the Commission under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on June 29, 2021, including any amendments or reports filed for the purpose of updating such description.

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Item 8.

    Exhibits.

    Exhibit
    Number

    Exhibit Description

    Filed
    Herewith

    Incorporated by
    Reference herein from
    Form or Schedule

    Filing Date

    SEC File/
    Reg.
    Number

    4.1

    Second Amended and Restated Memorandum and Articles of Association of ProKidney Corp.

    Form 8-K
    (Exhibit 3.1)

    7/15/2022

    001-40560

    5.1

    Opinion of Walkers (Cayman) LLP

    X


    23.1

    Consent of Ernst & Young LLP, independent registered public accounting firm

    X

    23.2

    Consent of Walkers (Cayman) LLP (included in Exhibit 5.1)

    X

    24.1

    Power of Attorney (included on the signature page hereof)

    X

    99.1+

    ProKidney Corp. 2022 Incentive Equity Plan

    Form 8-K
    (Exhibit 10.11)

    7/15/2022

    001-40560

    107

    Calculation of registration fee

    X

    + Management contract or compensatory plan or arrangement.


    Signatures

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Winston-Salem, State of North Carolina, on March 20, 2025.

    PROKIDNEY CORP.

    By:

    /s/ Bruce Culleton, M.D.

    Bruce Culleton, M.D.

    Chief Executive Officer

     


    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints each of Bruce Culleton, M.D. and James Coulston, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dated indicated.

    Signature

    Title

    Date

     

     

     

     

     

    /s/Bruce Culleton, M.D.

    Chief Executive Officer and Director
    (Principal Executive Officer)

    March 20, 2025

    Bruce Culleton, M.D.

    /s/James Coulston, CPA

    Chief Financial Officer (Principal Financial and Accounting Officer)

    March 20, 2025

    James Coulston, CPA

    /s/Pablo Legorreta

    Chairman

    March 20, 2025

    Pablo Legorreta

    /s/William F. Doyle

    Director

    March 20, 2025

    William F. Doyle

    /s/Jennifer Fox

    Director

    March 20, 2025

    Jennifer Fox

    /s/José Ignacio Jimenez Santos

    Director

    March 20, 2025

    José Ignacio Jimenez Santos

    /s/Alan M. Lotvin, M.D.

    Director

    March 20, 2025

    Alan M. Lotvin, M.D.

    /s/Brian J.G. Pereira, M.D.

    Director

    March 20, 2025

    Brian J.G. Pereira, M.D.

     

     

    /s/Uma Sinha, Ph.D.

    Director

    March 20, 2025

    Uma Sinha, Ph.D.

     


    Get the next $PROK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PROK

    DatePrice TargetRatingAnalyst
    9/30/2024Neutral
    JP Morgan
    9/10/2024$6.00Buy
    Guggenheim
    3/7/2024$3.00Equal-Weight
    Morgan Stanley
    1/2/2024Buy → Neutral
    BofA Securities
    7/25/2023$16.00Buy
    BTIG Research
    12/21/2022$15.00Buy
    Jefferies
    11/10/2022$13.00Equal-Weight
    Morgan Stanley
    10/18/2022$18.00Buy
    UBS
    More analyst ratings

    $PROK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan initiated coverage on ProKidney Corp.

      JP Morgan initiated coverage of ProKidney Corp. with a rating of Neutral

      9/30/24 7:50:41 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on ProKidney Corp. with a new price target

      Guggenheim initiated coverage of ProKidney Corp. with a rating of Buy and set a new price target of $6.00

      9/10/24 7:56:11 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley resumed coverage on ProKidney Corp. with a new price target

      Morgan Stanley resumed coverage of ProKidney Corp. with a rating of Equal-Weight and set a new price target of $3.00

      3/7/24 7:33:04 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ProKidney Corp.

      SC 13G/A - PROKIDNEY CORP. (0001850270) (Subject)

      11/8/24 10:13:46 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ProKidney Corp.

      SC 13G/A - PROKIDNEY CORP. (0001850270) (Subject)

      10/22/24 3:32:15 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by ProKidney Corp.

      SC 13D/A - PROKIDNEY CORP. (0001850270) (Subject)

      6/25/24 4:08:10 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $276,366 worth of Class A Ordinary Shares (387,393 units at $0.71) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/24/25 4:15:43 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $18,690 worth of Class A Ordinary Shares (25,000 units at $0.75) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/21/25 4:37:34 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $74,820 worth of Class A Ordinary Shares (100,000 units at $0.75) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/18/25 4:15:51 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    SEC Filings

    See more
    • ProKidney Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure

      8-K - PROKIDNEY CORP. (0001850270) (Filer)

      5/30/25 4:02:02 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PROKIDNEY CORP. (0001850270) (Filer)

      5/12/25 4:18:14 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by ProKidney Corp.

      10-Q - PROKIDNEY CORP. (0001850270) (Filer)

      5/12/25 4:17:58 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Leadership Updates

    Live Leadership Updates

    See more
    • ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.

      Refined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company's highest priority marketDiscontinued the ex-U.S.-based PROACT 2 trial and focused Company resources on PROACT 1 to expedite enrollment and accelerate estimated topline data readout to Q3 2027 WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentiall

      9/3/24 7:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Reports Business Updates and First Quarter 2024 Financial Results

      Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD with Dr. Arnold Silva and Dr. Steven Coca and a recap of the RMCL-002 data is planned for May 28, 2024On schedule to resume manufacturing and PROACT 1 Phase 3 trial, commence PROACT 2 Phase 3 trial, and readout interim results from the ongoing REGEN-007 Phase 2 trial in mid-2024Strengthened leadership team with appointment of two key hires across Clinical and Technical OperationsEnded the first quarter with $329 million in cash and cash equivalents and marketable securities, su

      5/10/24 7:00:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

      WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023. "We are very excited about the future of ProKidney. Building on the positive interim Phase 2 data that we released last Fall for rilparencel (which we sometimes refer to as REACT®) demonstrating the potential to preserve kidney function in patients with type 2 diabetes mellitus and advanced kidney disease, we look forward to the REGEN-007 Phase 2 interim data readout mid-year," said Bruce Culleton, Ch

      3/21/24 7:49:56 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Financials

    Live finance-specific insights

    See more
    • ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

      Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and both PROACT 1 and PROACT 2 Phase 3 trialsManagement to host live webcast today at 8:00 a.m. ET WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) --  ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced positive interim results from the Phase 2 REGEN-007 trial evaluating the Company's renal autologous cell therapy, rilparencel, in patients with CKD caused by diabetes and provided clinical

      6/10/24 6:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Reports Third Quarter Financial Results

      WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023. "Building off of our positive corporate update, and with nearly $400 million in cash, cash equivalents and marketable securities as of September 30th of this year, ProKidney continues to be well capitalized to continue executing on both of our Phase 2 and Phase 3 trials in high-risk CKD patients in need," said James Coulston, Chief Financial Officer at ProKidney. "With cash expected to fund operations into the

      11/14/23 6:05:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

      Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients Focusing Phase 3 development program on patients with Stage 3b and 4 diabetic CKD at highest risk of advancing to kidney failure and need for renal replacement therapy Dr. Bruce Culleton appointed ProKidney CEO following Dr. Tim Bertram's transition to advisory role Sufficient capital to fund operations into fourth quarter 2025 ProKidney to host conference call and webcast tomorrow at 8:00 a.m. ET WINSTON-SALEM, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellu

      11/13/23 5:02:13 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PROK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

      Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional details on the accelerated pathway are expected in mid-2025 after our planned Type B meeting with the FDAEnded the first quarter with $328.5 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported financial results

      5/12/25 4:15:00 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Reports Full Year 2024 Financial Results and Business Highlights

      Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel's path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, and securing $140 million of equity to extend cash runway into mid-2027In Q4 2024, the FDA confirmed in a Type B meeting that the accelerated approval pathway is available for rilparencel if an acceptable surrogate endpoint, which may include eGFR slope, is used; additional details expected in mid-2025Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025; interim data from June 2024 showed kidney function stabilization for 18 months in patients with advanced CKD and diabetesEnd

      3/17/25 7:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event. 43rd Annual J.P. Morgan Healthcare ConferenceDate:January 15, 2025Time:7:30am PSTFormat:PresentationWebcast:Link   The live webcast will also be accessible through the "Events" section of the Investor Relations tab within ProKidney's website

      1/7/25 7:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $276,366 worth of Class A Ordinary Shares (387,393 units at $0.71) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/24/25 4:15:43 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $18,690 worth of Class A Ordinary Shares (25,000 units at $0.75) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/21/25 4:37:34 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $74,820 worth of Class A Ordinary Shares (100,000 units at $0.75) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/18/25 4:15:51 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care